Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Acquired by Two Sigma Investments LP

Two Sigma Investments LP boosted its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 228.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 480,298 shares of the company's stock after purchasing an additional 334,042 shares during the period. Two Sigma Investments LP owned approximately 0.22% of Sana Biotechnology worth $783,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of SANA. Millennium Management LLC raised its stake in shares of Sana Biotechnology by 604.8% in the 4th quarter. Millennium Management LLC now owns 728,901 shares of the company's stock valued at $1,188,000 after acquiring an additional 625,481 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Sana Biotechnology by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,056,512 shares of the company's stock valued at $1,722,000 after acquiring an additional 8,666 shares during the period. Geode Capital Management LLC raised its stake in shares of Sana Biotechnology by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company's stock valued at $5,206,000 after acquiring an additional 26,601 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Sana Biotechnology by 44.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,557,496 shares of the company's stock valued at $2,538,000 after acquiring an additional 478,596 shares during the period. Finally, Jane Street Group LLC raised its stake in shares of Sana Biotechnology by 287.2% in the 4th quarter. Jane Street Group LLC now owns 367,855 shares of the company's stock valued at $600,000 after acquiring an additional 272,862 shares during the period. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Trading Down 7.2%

SANA traded down $0.21 during trading hours on Wednesday, hitting $2.70. 2,932,692 shares of the company's stock were exchanged, compared to its average volume of 3,537,322. Sana Biotechnology, Inc. has a 12-month low of $1.26 and a 12-month high of $7.40. The firm has a 50 day moving average of $1.91 and a 200 day moving average of $2.34. The firm has a market cap of $608.79 million, a P/E ratio of -1.93 and a beta of 1.78.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.02. As a group, research analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $11.00 price target on shares of Sana Biotechnology in a research note on Thursday, April 24th. Jefferies Financial Group started coverage on shares of Sana Biotechnology in a research note on Friday, March 14th. They issued a "buy" rating and a $7.00 price target on the stock. Finally, Citizens Jmp upgraded shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price objective for the company in a report on Tuesday, March 18th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $10.80.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.